Skip to content

DMT research published in 2025

Page 5 of 6: studies 81 to 100 of 102, newest first. Back to the DMT overview

Studies

Examining the pharmacokinetic and pharmacodynamic interaction of N,N-dimethyltryptamine and harmine in healthy volunteers: Α factorial dose-escalation study.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie March 1, 2025 Klemens Egger, Javier Jareño Redondo, Jovin Müller et al. 14 citations

Ayahuasca, a traditional psychoactive Amazonian brew, usually contains N,N-dimethyltryptamine (DMT) and β-carboline (harmine, harmaline, tetrahydroharmine) monoamine oxidase inhibitors. However, the pharmacological interactions between these compounds remain incompletely understood. In this study, we developed an ayahuasca-inspired formulation containing DMT and harmine, aiming to...

Successful Natalizumab Treatment of Two Female Individuals With Susac Syndrome.

European Journal of Neurology March 1, 2025 Agni M Konitsioti, Rafael Grajewski, Mark Schlamann et al. 1 citation

Susac syndrome is a rare autoimmune endotheliopathy that affects the central nervous system, retina, and inner ear, characterized by encephalopathy, branch retinal artery occlusions, and sensorineural hearing loss. Due to the heterogeneity of its presentation, early diagnosis, and treatment remain challenging. To evaluate the clinical outcomes and radiological responses in two patients with...

DOI: 10.1111/ene.70103 (opens in new tab) Full text (opens in new tab) DMT Disease-modifying therapy MRI Neuroimmunology +4

The Antidepressant Effects of Vaporized N,N-Dimethyltryptamine: An Open-Label Pilot Trial in Treatment-Resistant Depression.

Psychedelic Medicine March 1, 2025 Marcelo Falchi-Carvalho, Handersson Barros, Raynara Bolcont et al. 16 citations

N,N-Dimethyltryptamine (DMT), a naturally occurring psychedelic tryptamine contained in the indigenous ayahuasca brew, has shown antidepressant effects. This open-label clinical trial investigates for the first time the efficacy of vaporized DMT in treatment-resistant depression (TRD). Six TRD patients participated in an open-label, fixed-order, dose-escalation study, receiving a lower (15 mg)...

Cardiac effects of two hallucinogenic natural products, N,N-dimethyl-tryptamine and 5-methoxy-N,N-dimethyl-tryptamine.

Scientific Reports February 25, 2025 Joachim Neumann, Tobias Dietrich, Karyna Azatsian et al. 2 citations

It is unclear whether hallucinogenic tryptamine derivatives namely N,N-dimethyl-tryptamine (DMT) and 5-methoxy-N,N-dimethyl-tryptamine (5-MeO-DMT) exert positive inotropic effects in the human heart. Therefore, we measured the inotropic effects of these drugs in isolated left and right atrial preparations of mice that overexpress human 5-HT4 receptors (5-HT4-TG) and preparations from wild type...

DOI: 10.1038/s41598-025-91400-6 (opens in new tab) Full text (opens in new tab) Serotonin sign N,N-Dimethyl-Tryptamine DMT 5-ht4 receptor 5-Methoxy-N,N-Dimethyl-Tryptamine 5-MEO-DMT +8

Long-Term Mental Health and Wellbeing Outcomes Associated with Naturalistic Ayahuasca Consumption.

Journal of Psychoactive Drugs February 20, 2025 Broc A. Pagni, Andreas Halman, Jerome Sarris et al. 7 citations

The durability of ayahuasca's effects on mental health and the influence of clinical diagnoses on therapeutic response is unclear. Adults with no prior exposure to ayahuasca (n = 66) participating in neo-shamanic ayahuasca ceremonies completed questionnaires at baseline, 7 days, and 1, 6, and 12 months. Mixed models were used to characterize temporal trajectories in mental health, alcohol and...

Sex Differences in Religious Beliefs Before and After an Entity Encounter During an Ayahuasca Experience.

Journal of Psychoactive Drugs February 13, 2025 Yitong Xin, Roland R. Griffiths, Alan K. Davis 1 citation

An interesting aspect of entity encounters during psychedelic experiences is their ability to transform one's religious beliefs. However, little is known about sex differences in these transformations. This study investigates sex differences in changes in religious beliefs before and after an entity encounter among ayahuasca users. Data were collected via an anonymous Internet-based survey (N =...

DMT-induced shifts in criticality correlate with ego-dissolution

bioRxiv February 8, 2025 Mona Irrmischer, Marco Aqil, Lisa Luan et al. 4 citations preprint

ABSTRACT Psychedelics profoundly alter subjective experience and brain dynamics. Brain oscillations express signatures of near-critical dynamics, relevant for healthy function. Alterations in the proximity to criticality have been suggested to underlie the experiential and neurological effects of psychedelics. Here, we investigate the effects of a psychedelic substance (DMT) on the criticality...

Evaluating the value and risks of psychedelics for psychiatric medicine: a clinical perspective.

Expert Review of Neurotherapeutics February 1, 2025 Donatella Marazziti, Francesco Weiss, Riccardo Gurrieri et al. 4 citations

After a long period of obscurantism, a possible role of psychedelics in clinical practice has progressively become a tangible perspective during the last two decades. However, the resounding enthusiasm linked to such 'psychedelic renaissance' runs the risk to unduly minimize the possible hazards associated with these compounds, while expanding their alleged benefits to improbable panacea-like...

Clinical Pharmacokinetics of N,N-Dimethyltryptamine (DMT): A Systematic Review and Post-hoc Analysis.

Clinical Pharmacokinetics February 1, 2025 Katelijne V. van der Heijden, Marije E. Otto, Jan W. Schoones et al. 7 citations

N,N-Dimethyltryptamine (DMT) is currently being studied for its therapeutic potential in various psychiatric disorders. An understanding of its pharmacokinetics (PK) is essential to determine appropriate dose ranges in future clinical studies. We conducted a systematic literature review on the PK of DMT. Clinical studies that administered known amounts of DMT and reported PK data and/or...

DOI: 10.1007/s40262-024-01450-8 (opens in new tab) Full text (opens in new tab) DMT Psychedelics Pharmacology Mental health treatment

Detailing a Pilot Study: The "Code of Reality" Protocol, A Phenomenon of N,N-DMT Induced States of Consciousness

IPI Letters January 8, 2025 Danny Goler

This article reports on the discovery of a recurring visual phenomenon observed by individuals under the influence of exogenous N,N- Dimethyltryptamine (N,N- DMT) when observing a diffracted light pattern generated by a collimated 650 nm laser. Using a structured protocol, a pilot study revealed consistent descriptions of coherent geometric structures and symbols resembling "code." This report...

Translational reinterpretation of ancestral healing rituals: Structured physiological modulation through adaptive biological responses.

Explore 2025 João Francisco Pollo Gaspary, Alfred Lee Edgar, Fernanda Peron Gaspary et al.

Ancestral healing rituals have long been embedded in cultural traditions as symbolic practices. However, emerging evidence suggests these rituals may act as structured behavioral interventions capable of eliciting adaptive physiological responses. This study proposes a translational reinterpretation of ancestral healing rituals through the lens of contemporary redox biology, systems physiology,...

DOI: 10.1016/j.explore.2025.103274 (opens in new tab) Full text (opens in new tab) Dimethyltryptamine Ancestral healing rituals Behavioral entrainment Electrochemical microgradients +4

Clinical pharmacokinetics of N,N-dimethyltryptamine (DMT): a systematic review and post-hoc analysis

Leiden Repository 2025 Katelijne V. van der Heijden, Marije E. Otto, Jan W. Schoones et al.

BACKGROUND AND OBJECTIVE\nMETHODS\nRESULTS\nCONCLUSION\nN,N-Dimethyltryptamine (DMT) is currently being studied for its therapeutic potential in various psychiatric disorders. An understanding of its pharmacokinetics (PK) is essential to determine appropriate dose ranges in future clinical studies. We conducted a systematic literature review on the PK of DMT.\nClinical studies that administered...

DOI: 10.1007/s40262-024-01450-8#citeas (opens in new tab) Pharmacokinetics Bolus digestion Volume of distribution Dosing +2

Intoxication Associated with Ayahuasca Consumption, Characterization, and Comparative Analysis of the Beverage's Components: A Case Report.

Revista Colombiana de psiquiatria 2025 Edgar A Estrella-Parra, José G. Avila-Acevedo, Ana M García-bores et al.

Ayahuasca is a psychotropic beverage from South America, derived from Banisteriopsis caapi and Psychotria viridis. The beverage contains alkaloids such as β-carbolines and dimethyltryptamine (DMT), which alter the psychoactive functions associated with perception and thought processes. Its consumption in the countries of origin, such as Brazil, Colombia, and Peru, is prevalent. Its use has been...

PolDrugs 2025: results of the third edition of the nationwide study on psychoactive substance use in the context of psychiatry and harm reduction.

Frontiers in Psychiatry 2025 Julia Marek, Magdalena Domek-Gumprecht, Agata Macionga et al.

PolDrugs is a biennial epidemiological study aimed at analyzing patterns of mostly illicit psychoactive substance use in Poland in the context of psychiatry and harm reduction. This survey was held for the third time, and its results were compared to the last two editions. The survey was conducted as an online survey with 37 closed-ended single-choice questions and 3 multiple-choice questions....

Human neuroimaging: fMRI.

International review of neurobiology 2025 Matthew B. Wall, Robin Carhart-Harris

Human neuroimaging with functional Magnetic Resonance Imaging has been a key feature of the current wave of psychedelic research, in both healthy and clinical populations. The available data has suggested that classic psychedelics (psilocybin, LSD, DMT) have a characteristic effect of acutely and profoundly disrupting the normal pattern of resting-state connectivity in the human brain, and that...

The protective effect of DMT against neurodegeneration.

International review of neurobiology 2025 Ede Frecska, Attila Kovács, Attila Szabo 2 citations

This paper explores the therapeutic potential of DMT in neuroprotective strategies, particularly concerning ischemia-reperfusion injury (IRI) and neurodegenerative disorders. Besides its potent serotonin receptor actions, DMT is also an endogenous agonist of the sigma-1 receptor (Sig-1R). Sigma receptors are a unique family of proteins with high expression in the brain and spinal cord and have...

DOI: 10.1016/bs.irn.2025.04.010 (opens in new tab) Full text (opens in new tab) Serotonin DMT Alzheimer’s disease Amyotrophic lateral sclerosis +8

Evaluation of the peak experience scale as a rapid assessment tool for the strength of a psychoactive experience with 5-MeO-DMT.

Frontiers in Psychology 2025 Johannes T. Reckweg, Natasha L. Mason, Eef L. Theunissen et al. 2 citations

A three-item Peak Experience Scale (PES) was developed to rapidly evaluate the strength of the psychoactive experience, and to guide the dosing regimen, of the psychedelic 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT; mebufotenin). This paper aims to compare the PES with a range of established questionnaires designed to evaluate the psychedelic experience. Data were gathered from three separate...

Serotonergic psychedelic 5-MeO-DMT alters plasticity-related gene expression and generates anxiolytic effects in stressed mice.

Molecular Psychiatry 2025 Margareth Nogueira, Daiane C Ferreira Golbert, Richardson Menezes et al. 18 citations

Serotonergic psychedelics have potential therapeutic effects in treating anxiety and mood disorders, often after a single dose, and are suggested to have plasticity-inducing action. However, a comprehensive mechanism of action is still lacking. Here, we investigated how a single dose of the short-acting 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) acts on gene expression from microdissected...

DOI: 10.1038/s41380-024-02655-w (opens in new tab) Full text (opens in new tab) Psychopharmacology Anxiety research Natural compounds

Associations between psychedelic use and cannabis use disorder in a nationally representative sample.

Drug and Alcohol Dependence 2025 James M Zech, David B. Yaden, Grant Jones 9 citations

Cannabis Use Disorder (CUD) is an increasingly prevalent disorder affecting millions of Americans each year. Psychedelic compounds have recently been investigated for their therapeutic potential in treating substance use disorders, yet no prior work has examined the relationship between naturalistic use of specific psychedelic compounds and rates of disordered cannabis use. Using a nationally...

Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression

American Journal of Psychiatry 2025 Johannes G. Ramaekers, Johannes T. Reckweg, Natasha L. Mason 25 citations

Unlike classical antidepressants, psychedelics such as psilocybin have been shown to induce a rapid antidepressant response. In the wake of this development, interest has emerged in ultra-fast, short-acting psychedelics such as 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and N,N-dimethyltryptamine (DMT) with the expectation that these can produce rapid antidepressant effects following an...

DOI: 10.1176/appi.ajp.20230890 (opens in new tab) 5-MEO-DMT Depression Psychedelic drugs Quick-onset treatment +3